Abec­ma sales dis­ap­point again as BC­MA com­pe­ti­tion ramps up, FDA ad­comm looms

Fourth-quar­ter US sales of Bris­tol My­ers Squibb’s BC­MA-tar­get­ing CAR-T ther­a­py Abec­ma last year de­clined by 40% com­pared to the same pe­ri­od in 2022, pri­mar­i­ly due to com­pet­i­tive pres­sure.

Abec­ma pulled in $56 mil­lion in US rev­enue and $100 mil­lion to­tal world­wide, BMS re­port­ed in its earn­ings up­date Fri­day, fig­ures that rep­re­sent­ed 40% and 20% drops, re­spec­tive­ly. Com­pe­ti­tion from oth­er BC­MA-tar­get­ing drugs drove the de­cline, a com­pa­ny spokesper­son told End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER